Provided by Tiger Trade Technology Pte. Ltd.

Ovid Therapeutics Inc.

2.30
-0.1600-6.50%
Post-market: 2.340.0400+1.74%19:59 EDT
Volume:2.02M
Turnover:4.75M
Market Cap:347.30M
PE:-9.89
High:2.45
Open:2.42
Low:2.29
Close:2.46
52wk High:2.72
52wk Low:0.2425
Shares:151.00M
Float Shares:120.00M
Volume Ratio:0.49
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2325
EPS(LYR):-0.2325
ROE:-17.51%
ROA:-21.82%
PB:2.66
PE(LYR):-9.89

Loading ...

Ovid Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Ovid Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Oct 28, 2025

Oppenheimer upgrades Ovid Therapeutics (OVID) to a Buy

TIPRANKS
·
Oct 09, 2025

William Blair Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

TIPRANKS
·
Oct 04, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Occidental Petroleum , GameStop, Alphabet

Reuters
·
Oct 03, 2025

Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Eye Another Interest Rate Cut for 2025

MT Newswires Live
·
Oct 03, 2025

Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million

MT Newswires Live
·
Oct 03, 2025

BUZZ-Ovid Therapeutics jumps after seizure treatment shows promise in trial

Reuters
·
Oct 03, 2025

Ovid Shares Leap Premarket on Positive Study Results, Financing Pact

Dow Jones
·
Oct 03, 2025

Top Premarket Gainers

MT Newswires Live
·
Oct 03, 2025

Ovid Therapeutics Shares up 25.6% Premarket After Co Reports Early-Stage Data for Seizure Treatment

THOMSON REUTERS
·
Oct 03, 2025

Ovid Therapeutics prices private placement up to $175M in gross proceeds

TIPRANKS
·
Oct 03, 2025

Ovid Therapeutics Announces $175 Million Private Placement to Fund Pipeline Through 2028

Reuters
·
Oct 03, 2025

Ovid Therapeutics Announces Positive Phase 1 Results for OV329, Plans Phase 2a Trial for Drug-Resistant Focal Onset Seizures in 2026

Reuters
·
Oct 03, 2025

Ovid Therapeutics Inc - Ov329 Safety Results Preferable to Marketed Asms

THOMSON REUTERS
·
Oct 03, 2025

Ovid Therapeutics Inc - Ov329 Matched or Exceeded Vigabatrin Inhibition on Tms

THOMSON REUTERS
·
Oct 03, 2025

Ovid Announces Positive Topline Results for the Next-Generation Gaba-Aminotransferase Inhibitor, Ov329, That Demonstrate Strong Inhibitory Activity and a Potential Best-in-Category Safety Profile

THOMSON REUTERS
·
Oct 03, 2025